Postmenopausal Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy

Postmenopausal women with hormone receptor‐positive, HER2‐negative, early breast cancer involving 1–3 lymph nodes who are undergoing endocrine therapy and have an Oncotype DX recurrence score of 0–25 can safely avoid chemotherapy, according to findings from the phase III RxPonder study.